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appearance of dying cells) does not
convey information on immunogenicity
(Kroemer et al., 2009). As an example,
necrotic cancer cells are far less immuno-
genic than some types of apoptotic tumor
cells, which potently stimulate the
immune system due to a specific constel-
lation of danger-associated molecular
signals that are exposed by and secreted
from dying cells (Panaretakis et al.,
2009). Hence, it may be speculated—yet
remains to be proven—that the induction
of necrosis (as opposed to potentially
immunogenic apoptosis) might constitute
a particular strategy of Shigella to sabo-
tage the immune system.
In summary, the work published in this
issue by Carneiro and colleagues (Car-
neiro et al., 2009) is of dual merit. First,
Carneiro et al. demonstrate that nonmye-
loid cells infected by Shigella die through
a regulated form of necrotic cell death,
lending further support to the notion that
necrosis can indeed be programmed.
Second, they extend our knowledge on
how the interplay between NLR proteins
and cell death programs can affect the
innate immune response.
ACKNOWLEDGMENTS
Oliver Kepp is acknowledged for help in figure
preparation.
REFERENCES
Baines, C.P., Kaiser, R.A., Purcell, N.H., Blair, N.S.,
Osinska, H., Hambleton, M.A., Brunskill, E.W.,
Sayen, M.R., Gottlieb, R.A., Dorn, G.W., et al.
(2005). Nature 434, 658–662.
Carneiro, L.A.M., Travassos, L.H., Soares, F., Tat-
toli, I., Magalhaes, J.G., Bozza, M.T., Plotkowski,
M.C., Sansonetti, P.J., Molkentin, J.D., Philpott,
D.J., et al. (2009). Cell Host Microbe 5, this issue,
123–136.
Galluzzi, L., Brenner, C., Morselli, E., Touat, Z., and
Kroemer, G. (2008). PLoS Pathog. 4, e1000018.
Hitomi, J., Christofferson, D.E., Ng, A., Yao, J.,
Degterev, A., Xavier, R.J., and Yuan, J. (2008).
Cell 135, 1311–1323.
Kroemer, G., Galluzzi, L., and Brenner, C. (2007).
Physiol. Rev. 87, 99–163.
Kroemer, G., Galluzzi, L., Vandenabeele, P.,
Abrams, J., Alnemri, E.S., Baehrecke, E.H.,
Blagosklonny, M.V., El-Deiry, W.S., Golstein, P.,
Green, D.R., et al. (2009). Cell Death Differ. 16,
3–11.
Panaretakis, T., Kepp, O., Brockmeier, U., Tes-
niere, A., Bjorklund, A.C., Chapman, D.C., Durchs-
chlag, M., Joza, N., Pierron, G., van Endert, P.,
et al. (2009). EMBO J., in press. Published online
January 22, 2009. 10.1038/emboj.2009.
Perkins, N.D. (2007). Nat. Rev. Mol. Cell Biol. 8,
49–62.
Suzuki, T., Franchi, L., Toma, C., Ashida, H.,
Ogawa, M., Yoshikawa, Y., Mimuro, H., Inohara,
N., Sasakawa, C., and Nunez, G. (2007). PLoS
Pathog. 3, e111.
Vande Velde, C., Cizeau, J., Dubik, D., Alimonti, J.,
Brown, T., Israels, S., Hakem, R., and Greenberg,
A.H. (2000). Mol. Cell. Biol. 20, 5454–5468.
Cell Host & Microbe
PreviewsMammalian PGRPs in the Spotlight
Ivo Gomperts Boneca1,2,*
1Institut Pasteur, Group of Biology and Genetics of the Bacterial Cell Wall, 25–28 rue du Docteur Roux, Paris 75015, France
2INSERM, Group Avenir, Paris 75015, France
*Correspondence: bonecai@pasteur.fr
DOI 10.1016/j.chom.2009.01.007
Peptidoglycan-recognition proteins (PGRPs) play a central role in the insect innate immune response to
bacteria. In this issue of Cell Host & Microbe, Saha et al. (2009) report that the mammalian PGRP,
PGLYRP-2, functions as a cytokine-like molecule in a PG-induced arthritis model.Cell Host & Microbe 5tion as a coreceptor and was not essen-
tial in mediating the biological activity of
PG. Subsequent studies in insects and
in particular on Drosophila indicated that
activation of the innate immune response
was mediated exclusively by sensing of
PG. This activation involved two distinct
pathways: the TOLL pathway allowing
detection of Gram-positive bacteria
and the IMD pathway for Gram-negative
bacteria. Activation of both pathways
occurred by sensing of PG by PG-recog-
nition proteins (PGRPs). Insect PGRPs
have since been shown to mediate
several responses to PG, such as induc-
tion of antimicrobial peptide production,itself mediate these activities, suggesting
that eukaryotes have evolved to detect
actively replicating bacteria (since bac-
teria degrade and recycle their pepti-
doglycan as they replicate).
The large spectrum of biological activi-
ties mediated by PG fragments raise an
important question: How are these PG
fragments detected by the host? Are
there different receptors mediating each
effect? Are there local tissue specificities
in terms of receptors? Are there local
differences in bioavailability of distinct
PG fragments?
The first proposed receptor of PG was
CD14. However, CD14 seemed to func-Peptidoglycan (PG) is a major component
of the bacterial cell wall. Hence, it is an
excellent marker of bacterial origin, in
particular due to its unique composition
of L and D amino acids. Eukaryotes,
from the simplest unicellular yeast to
higher eukaryotes like humans, have
evolved to use PG to detect the presence
of bacteria and mount an appropriate
response. In the 1970s and 1980s, several
different research groups identified awide
variety of biological effects of PG ranging
from induction of Gram-positive septic
shock to the induction of slow-wave sleep
(Boneca, 2005). PG degradation products
rather than the insoluble macromolecule, February 19, 2009 ª2009 Elsevier Inc. 109
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the prophenoloxidase cascade, and
hydrolysis of PG with consequent down-
regulation of the immune response (Royet
and Dziarski, 2007).
In contrast, in mammals Toll-like
receptor (TLR) 2 was proposed to be the
PG receptor with CD14 as coreceptor.
The role of TLR2 in PG sensing remains
highly controversial, but mammals also
were shown to encode in their genomes
representatives of the PGRP family.
Mice and humans have four distinct
PGRPs: PGLYRP-1,-2, -3, and -4. Never-
theless, studies of themammalian PGRPs
never supported a direct role for these
proteins in PG sensing in mammals. The
Dziarski group and others have been
elucidating the role of these mammalian
PGRPs. PGLYRP-1, -3, and -4 seem to
function as antimicrobial peptides, while
PGLYRP-2 is produced by the liver and
secreted into the blood stream and
carries a PG amidase hydrolytic activity
characteristic of the catalytic PGRPs.
Thus, these PGRPs seem to belong to
the innate immune arm of effector mole-
cules, such as antimicrobial peptides and
C-type lectins, among others. Most impor-
tantly, mice deficient for either PGLYRP-1
or -2 did not display any striking pheno-
type or enhanced susceptibility to bacte-
rial infections (Dziarski et al., 2003; Xu
et al., 2004) in contrast to Drosophila
deficient for PGRP-SA or PGRP-LC (Royet
and Dziarski, 2007).
Accordingly, Nod1 and Nod2 proteins,
two intracellular receptors of the innate
immune system, were shown to be the
long-sought receptors of PG fragments,
raising again the question of the exact
role of mammalian PGRPs in innate
immunity. In this issue, Saha and
colleagues from the Dziarski laboratory
bring a new and exciting view of the role
of PGLYRP-2. One frequent consequence
of bacterial infections such as strepto-
coccal rheumatic fever is the develop-
ment of arthritis. Arthritis can be induced
in several models by administration of
PG, and recently, Joosten and colleagues
have shown the role of Nod1 and Nod2 in
an intraarticular injection model (Joosten
et al., 2008). Usually, arthritis develops in
the absence of local bacterial infection,
suggesting that the proinflammatory PG
originates from a distant location in the
body. Therefore, Saha and colleagues
used an intravenous model of acute110 Cell Host & Microbe 5, February 19, 2009arthritis in BalBC mice to determine
the roles of Nod-like receptors (NLRs),
TLRs, and mammalian PGRPs, in partic-
ular PGLYRP-2. It was expected that
PGLYRP-2 would have an anti-inflamma-
tory role similar to the amidase-active
PGRPs of Drosophila. From this perspec-
tive, PGLYRP-2 would function as a scav-
anger protein hydrolyzing circulating PG
to downmodulate its biological proper-
ties. However, PGLYRP-2’s known cat-
alytic properties suggested otherwise.
Indeed, the muropeptide N-acetylglucos-
amine-b1,4-N-acetymuramyl-L-alanyl-D-
g-glutamyl-meso-diaminopimelic acid
(GMTriPDAP) is the minimal structure that
PGLYRP-2 can hydrolyze, releasing the
peptide moiety from the disaccharide
(Wang et al., 2003). GMTriPDAP is a Nod1
ligand. However, the tripeptide (TriPDAP)
remains a potent Nod1 ligand comparable
to GMTriPDAP (Girardin et al., 2003). This
suggests that PGLYRP-2 is unlikely to
function as a scavenger protein to down-
modulate Nod1. As to Nod2, its ligands
muramyldipeptide (MDP) or GMDP are
not substrates for PGLYRP-2, again indi-
cating that if there were a role of
PGLYRP-2 in arthritis, it would be an
unexpected one.
Saha and colleagues show in their intra-
venous injection model that induction of
arthritis by PG and by MDP not only
requiresNod2butalsoPGLYRP-2(Figure1)
(Saha et al., 2009). PGLYRP-2-deficient
mice failed to develop arthritis, as was the
case for Nod2-deficient mice. PG activates
Nod2, which in turn induces the production
of PGLYRP-2. PGLYRP-2 is required for
the induction of cytokines, chemokines,
and some of their receptors. Interestingly,
the defect in the response of PGLYRP-2-
deficient mice to MDP was exclusively
local. In the liver, the main organ producing
PGLYRP-2, the responsetoMDPwas iden-
tical in BalBC- and PGLYRP-2 deficient
mice, indicating that these mice did not
have an intrinsic defect of their innate
immune response as previously shown.
Hence, a crucial question remained to
be answered. How did PGLYRP-2 exert
its proinflammatory effects? One could
argue that PGLYRP-2 could still rely on
its amidase activity to enhance the pro-
cessing of systemic PG togetherwith other
PG hydrolases such as lysozyme, thus
releasing PG fragments responsible for
the induction of arthritis. In contrast, the
amidase activity of PGLYRP-2was unlikelyª2009 Elsevier Inc.to be involved in the effect of MDP, since
(1) MDP is not a substrate for PGLYRP-2
(Wang et al., 2003), and (2) even if MDP
was cleaved by PGLYRP-2, the resulting
dipeptide could no longer activate Nod2
(Girardin et al., 2003). The authors show
using both HEK293 transfection assays
and reconstitution experiments with paw
fibroblasts that PGLYRP-2 functions as
a cytokine-like molecule to amplify the
MDP activation of Nod2. Furthermore,
the PGLYRP-2 cytokine-like function not
only enhances responses to PG or MDP,
but also to other stimuli mediated by
TLR2, TLR4, or IL-1. PGLYRP-2 alone did
not exert any effect on paw fibroblasts,
indicating that the cytokine-like effect
requires prior activation of cells.
This discovery raises several questions
that are probably the object of future
work. Apparently, in contrast to the intra-
articular injection model, administration
of Escherichia coli or Staphylococcus
aureus PG resulted in the same depen-
dence on Nod2 and PGLYRP-2, suggest-
ing that Nod1 does not play amajor role in
the intravenous injectionmodel. However,
the authors did not use Nod1-deficient
mice to address this issue. Furthermore,
there is clearly a difference in the kinetics
between PG- and MDP-induced arthritis.
The local joint inflammation might require
prior processing of PG, unlike the case for
MDP, to gain access to the local tissue. In
such a case, does serum PGLYRP-2 facil-
itate digestion and delivery of PG to the
joint? Why is it only PG that can exert
this effect, since activation of TLR2 or
TLR4 can also induce expression of
PGLYRP-2? Is PG binding to PGRLY-2
required for the cytokine-like function? Is
there a dedicated cell-surface receptor?
This work opens new perspectives in
the field of PGRPs not only in mammals
but also in other systems such as
Drosophila. Indeed, the cytokine-like role
of PGLYRP-2 might be an ancestral trait
found in other members of the PGRP
family both in vertebrates and in inverte-
brates such as Drosophila. In fact, in
Drosophila, PGRPs can activate constitu-
tively the TOLL or IMD pathway in the
absence of negative regulators or upon
their overexpression. The parallel is
striking, since PGLYRP-1 exerts an antag-
onistic effect on PGLYRP-2 suggesting
that PGLYRP-1 and -2 might function
respectively as the PGRP-LF/LC tandem
in the IMD pathway (Maillet et al., 2008).
Cell Host & Microbe
PreviewsFigure 1. Local Cytokine-like Role of PGLYRP-2 in the Development of Joint Arthritis Induced by PG or MDP
Systemic injection of peptidoglycan orMDP induces an acute arthritis of the joints of the feet in BalBCmice. The local response to PG orMDP requires a functional
Nod2 pathway (blue arrows). Surprisingly, the local inflammation also requires PGLYRP-2, and PGLYRP-2/ BalBC mice do not develop arthritis. Nod2
activation by PG or MDP induces the local production of PGLYRP-2 that amplifies the response by a cytokine-like mechanism (red arrows) that is independent
of the peptidoglycan hydrolytic amidase activity of PGLYRP-2. Another member of the PGRP family, PGLYRP-1, appears to have an antagonistic effect on the
cytokine-like role of PGLYRP-2. Hence, several questions arise on the mechanisms that PGLYRP-2 uses to exert its effects.Cell Host & Microbe 5D., and Dziarski, R. (2003). J. Biol. Chem. 278,
49044–49052.
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